Results 151 to 160 of about 3,056 (181)

2248 Clinical relevance of Donanemab treatment

Age and Ageing
Abstract Objective To assess in Alzheimer’s disease (ad), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs that matter to patients, care-partners, and clinicians ...
A Atri, A Wessels, E Doty, A Atkins, J Chandler, M Lu, W Ye, E Dennehy, D Brooks, J Sims, N Brookfield (Non-author Presenter)   +10 more
openaire   +1 more source

Donanemab in early symptomatic Alzheimer’s disease

Drug and Therapeutics Bulletin
Abstract Overview of: Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023;330:512-27
openaire   +2 more sources

Donanemab

Reactions Weekly
  +4 more sources

Use of Donanemab in Early Symptomatic Alzheimer Disease

JAMA, 2023
Nunzio, Pomara, Bruno Pietro, Imbimbo
openaire   +2 more sources

Alzheimerdemenz mit Donanemab gebremst

CME, 2023
openaire   +1 more source

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials

Healthcare (Switzerland), 2023
Azza Sarfraz, Ivan Cherrez Ojeda, Zouina Sarfraz   +2 more
exaly  

Lilly's Donanemab, will it be the light at the end of the tunnel?

The Innovation Medicine, 2023
Jianhong Dong, Ying Wang
openaire   +1 more source

Donanemab May Slow Alzheimer’s Progression

Psychiatric News, 2023
openaire   +1 more source

Donanemab/Lecanemab

Reactions Weekly
openaire   +1 more source

Donanemab in Early Alzheimer's Disease. Reply.

The New England journal of medicine, 2021
Mark A, Mintun, Alette M, Wessels, John R, Sims   +2 more
openaire   +1 more source